Intestinal dysbiosis fuels liver disease progression via NLRP3 in the Mdr2-/- mouse model of primary sclerosing cholangitis

被引：0

作者：

Liao, Lijun ^{[1
,2
]}

Schneider, Kai Markus ^{[1
]}

Eric, Galvez ^{[3
]}

Frissen, Mick ^{[1
]}

Marschall, Hanns-Ulrich ^{[4
]}

Sun, Huan ^{[1
]}

Hatting, Maximilian ^{[1
]}

Wahlstroem, Annika ^{[4
]}

Haybaeck, Johannes ^{[5
,6
]}

Puchas, Philip ^{[6
]}

Mohs, Antje ^{[1
]}

Jin, Peng ^{[1
]}

Bergheim, Ina ^{[7
]}

Nier, Anika ^{[7
]}

Hennings, Julia ^{[1
]}

Reissing, Johanna ^{[1
]}

Wolfgang, Zimmermann Henning ^{[1
]}

Longerich, Thomas ^{[8
]}

Strowig, Till ^{[3
]}

Liedtke, Christian ^{[1
]}

Cubero, Francisco Javier ^{[1
,9
]}

Trautwein, Christian ^{[1
]}

机构：

[1] Univ Hosp RWTH Aachen, Dept Internal Med 3, Aachen, Germany

[2] Tongji Univ, Shanghai East Hosp, Dept Anesthesiol & Pain Management, Shanghai, Peoples R China

[3] Helmholtz Ctr Infect Res GmbH, Braunschweig, Germany

[4] Wallenberg Inst & Labs, Dept Mol & Clin Med, Gothenburg, Sweden

[5] Univ Magdeburg, Dept Pathol, Magdeburg, Germany

[6] Med Univ Graz, Dept Pathol, Graz, Austria

[7] Univ Vienna, Mol Nutr Sci Div, Dept Nutr Sci, Vienna, Austria

[8] Heidelberg Univ Hosp, Liver Canc Ctr Heidelberg, Heidelberg, Germany

[9] Univ Complutense Madrid, Sch Med, Dept Immunol, Madrid, Spain

来源：

JOURNAL OF HEPATOLOGY | 2019年 / 70卷 / 01期

关键词：

D O I：

10.1016/S0618-8278(19)30177-X

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

PS-159

引用

页码：E100 / E100

页数：1

共 50 条

[21] Knockout of the Tachykinin Receptor 1 in the Mdr2-/- (Abcb4-/-) Mouse Model of Primary Sclerosing Cholangitis Reduces Biliary Damage and Liver Fibrosis
Ceci, Ludovica
Francis, Heather
Zhou, Tianhao
Giang, Thao
Yang, Zhihong
Meng, Fanyin
Wu, Nan
Kennedy, Lindsey
Kyritsi, Konstantina
Meadows, Vik
Wu, Chaodong
Liangpunsakul, Suthat
Franchitto, Antonio
Sybenga, Amelia
Ekser, Burcin
Mancinelli, Romina
Onori, Paolo
Gaudio, Eugenio
Glaser, Shannon
Alpini, Gianfranco
AMERICAN JOURNAL OF PATHOLOGY, 2020, 190 (11): : 2251 - 2266
[22] Glucagon like peptide-2 treatment improves liver and bile duct injury in the Mdr2-/- mouse model of sclerosing cholangitis
Menz, Moritz
Hinterleitner, Lorenz
Koenigshofer, Philipp
Halilbasic, Emina
Kunczer, Victoria
Stojakovic, Tatjana
Reiberger, Thomas
Fuchs, Claudia
Trauner, Michael
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E167 - E168
[23] Glucagon like Peptide (GLP)-2 Treatment Improves Liver and Bile Duct Injury in the Mdr2-/- Mouse Model of Sclerosing Cholangitis
Menz, Moritz
Hinterleitner, Lorenz
Koenigshofer, Philipp
Halilbasic, Emina
Kunczer, Victoria
Stojakovic, Tatjana
Reiberger, Thomas
Fuchs, Claudia Daniela
Trauner, Michael H.
HEPATOLOGY, 2018, 68 : 831A - 831A
[24] EXTRACELLULAR VESICLES ISOLATED FROM CHOLANGIOCYTES LACKING THE SECRETIN/SECRETIN RECEPTOR AXIS ATTENUATE LIVER FIBROSIS VIA CARGO MICRORNAS IN THE MDR2-/- MOUSE MODEL OF PRIMARY SCLEROSING CHOLANGITIS
Sato, Keisaku
Venter, Julie
Kennedy, Lindsey
Francis, Heather L.
Meng, Fanyin
Glaser, Shannon
Alpini, Gianfranco
GASTROENTEROLOGY, 2019, 156 (06) : S1215 - S1216
[25] Death Receptor Deficiency Augments Ductular Reaction and Hepatic Fibrosis in the Mdr2-/- Mouse Model of Sclerosing Cholangitis
Krishnan, Anuradha
Katsumi, Tomohiro
Guicciardi, Maria Eugenia
Bronk, Steven F.
Azad, Adiba
Gores, Gregory J.
HEPATOLOGY, 2018, 68 : 829A - 830A
[26] REGULATION OF CHOLANGIOCYTE PROLIFERATION BY THE miR-125B/HDC/HA/VEGF AXIS IN THE MDR2-/- MOUSE MODEL OF PRIMARY SCLEROSING CHOLANGITIS
Han, Y.
Meng, F.
Hargrove, L.
Graf, A.
Kennedy, L.
Francis, H.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S183 - S183
[27] The melatonin/MT1/miR-200b axis regulates biliary senescence and liver fibrosis in the Mdr2-/- mouse model of primary sclerosing cholangitis
Wu, Nan
Meng, Fanyin
Invernizzi, Pietro
Venter, Julie
Bernuzzi, Francesca
Alvaro, Domenico
Onori, Paolo
Franchitto, Antonio
Zhou, Tianhao
Francis, Heather L.
Kyritsi, Tina
Mancinelli, Romina
Gaudio, Eugenio
Alpini, Gianfranco
Glaser, Shannon S.
HEPATOLOGY, 2016, 64 : 178A - 178A
[28] Comparative potential of soybean lecithin and ursodeoxycholic acid against the progression of liver disease in the Mdr2-/- mouse model
Martel, M
St-Hilaire, W
Tuchweber, B
Bouchard, G
GASTROENTEROLOGY, 2005, 128 (04) : A260 - A260
[29] COMBINATION TREATMENTS OF AN IBAT INHIBITOR AND VARIOUS PPAR ISOFORM AGONISTS INDUCE DISTINCT CHANGES IN LIVER BIOCHEMISTRIES IN THE MDR2-/-MOUSE MODEL OF SCLEROSING CHOLANGITIS
Kudira, Ramesh
Pfuhler, Liva
Mullen, Mary
Whyte, Senyo
Bariya, Priya
Zhang, Wujuan
Setchell, Kenneth D. R.
Kostrub, Cory
Vig, Pamela
Miethke, Alexander
HEPATOLOGY, 2022, 76 : S1509 - S1509
[30] While small cholangiocytes contribute to liver fibrosis by enhanced phenotype transition, large cholangiocytes trigger liver fibrosis by enhanced senescence in the Mdr2-/- mouse model of primary sclerosing cholangitis (PSC)
Zhou, Tianhao
Wu, Nan
Francis, Heather L.
Venter, Julie
RamosLorenzo, Sugeily
McDaniel, Kelly
Kyritsi, Tina
Ehrlich, Laurent
Glaser, Shannon S.
Meng, Fanyin
Alpini, Gianfranco
HEPATOLOGY, 2016, 64 : 161A - 161A

← 1 2 3 4 5 →